Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 3 (2006), Issue 2 (February)

1. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.
   J Natl Cancer Inst, 98(3): 172-80. [Abstract] [Full-text]
2. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.
   J Natl Cancer Inst, 98(3): 163-71. [Abstract] [Full-text]
3. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases.
   Int J Cancer, 118(4): 879-88. [Abstract] [Full-text]
4. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
   J Clin Oncol, 24(5): 762-8. [Abstract] [Full-text]
5. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
   J Clin Oncol, 24(5): 755-61. [Abstract] [Full-text]
6. MZF1 possesses a repressively regulatory function in ERCC1 expression.
   Biochem Pharmacol, 71(6): 761-71. [Abstract] [Full-text]
7. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
   J Clin Oncol, 24(6): 863-71. [Abstract] [Full-text]
8. Molecular profiling of platinum resistant ovarian cancer.
   Int J Cancer, 118(8): 1963-71. [Abstract] [Full-text]
9. Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours.
   Int J Cancer, 118(8): 1884-91. [Abstract] [Full-text]
10. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival.
    Br J Cancer, 94(4): 552-60. [Abstract] [Full-text]
11. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    J Clin Oncol, 24(7): 1127-35. [Abstract] [Full-text]
12. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
    Expert Rev Anticancer Ther, 6(3): 437-43. [Abstract] [Full-text]
13. A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference.
    Gynecol Oncol, 101(1): 4-11. [Abstract] [Full-text]
14. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
    Gynecol Oncol, 101(1): 18-23. [Abstract] [Full-text]
15. Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality.
    Gynecol Oncol, 101(1): 152-7. [Abstract] [Full-text]
16. Primary insular carcinoid of the ovary.
    Gynecol Oncol, 101(1): 175-8. [Abstract] [Full-text]
17. PTEN expression in clear cell adenocarcinoma of the ovary.
    Gynecol Oncol, 101(1): 71-5. [Abstract] [Full-text]
18. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.
    Gynecol Oncol, 101(1): 97-101. [Abstract] [Full-text]
19. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China.
    Gynecol Oncol, 101(1): 92-6. [Abstract] [Full-text]
20. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
    Gynecol Oncol, 101(1): 126-31. [Abstract] [Full-text]
21. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
    Gynecol Oncol, 101(1): 114-9. [Abstract] [Full-text]
22. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Gynecol Oncol, 101(1): 28-39. [Abstract] [Full-text]
23. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer.
    Gynecol Oncol, 101(1): 12-7. [Abstract] [Full-text]
24. M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
    Gynecol Oncol, 101(1): 108-13. [Abstract] [Full-text]
25. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
    Gynecol Oncol, 101(1): 55-61. [Abstract] [Full-text]
26. Active coping mediates the association between religion/spirituality and quality of life in ovarian cancer.
    Gynecol Oncol, 101(1): 102-7. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.